These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 15579519

  • 1. Hemoglobin targets for the anemia of chronic kidney disease: a meta-analysis of randomized, controlled trials.
    Strippoli GF, Craig JC, Manno C, Schena FP.
    J Am Soc Nephrol; 2004 Dec; 15(12):3154-65. PubMed ID: 15579519
    [Abstract] [Full Text] [Related]

  • 2. Haemoglobin and haematocrit targets for the anaemia of chronic renal disease.
    Strippoli GF, Manno C, Schena FP, Craig JC.
    Cochrane Database Syst Rev; 2003 Dec; (1):CD003967. PubMed ID: 12535495
    [Abstract] [Full Text] [Related]

  • 3. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease.
    Strippoli GF, Navaneethan SD, Craig JC.
    Cochrane Database Syst Rev; 2006 Oct 18; (4):CD003967. PubMed ID: 17054191
    [Abstract] [Full Text] [Related]

  • 4. [Regarding the optimal hemoglobin target range in renal anemia].
    Maurin N.
    Med Klin (Munich); 2008 Sep 15; 103(9):633-7. PubMed ID: 18813886
    [Abstract] [Full Text] [Related]

  • 5. The blue cross blue shield assessment technology review: summary of findings.
    Bennett CL.
    Best Pract Res Clin Haematol; 2005 Sep 15; 18(3):423-31. PubMed ID: 15792916
    [Abstract] [Full Text] [Related]

  • 6. Should the target hemoglobin for patients with chronic kidney disease treated with erythropoietic replacement therapy be changed?
    Berns JS.
    Semin Dial; 2005 Sep 15; 18(1):22-9. PubMed ID: 15663760
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.
    Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, Pellegrini F, Ravani P, Jardine M, Perkovic V, Graziano G, McGee R, Nicolucci A, Tognoni G, Strippoli GF.
    Ann Intern Med; 2010 Jul 06; 153(1):23-33. PubMed ID: 20439566
    [Abstract] [Full Text] [Related]

  • 8. Treatment of anemia in renal transplantation: impact of a stricter application of hemoglobin targets.
    Gentil MA, Pérez-Valdivia MA, González-Roncero FM, López-Mendoza M, Cabello V, Bernal G, Suñer M, Pereira P.
    Transplant Proc; 2008 Nov 06; 40(9):2916-8. PubMed ID: 19010146
    [Abstract] [Full Text] [Related]

  • 9. Hemoglobin normalization trials in chronic kidney disease: what should we learn about quality of life as an end point?
    Covic A, Seica A, Gusbeth-Tatomir P, Goldsmith D.
    J Nephrol; 2008 Nov 06; 21(4):478-84. PubMed ID: 18651536
    [Abstract] [Full Text] [Related]

  • 10. Evidence for optimal hemoglobin targets in chronic kidney disease.
    Navaneethan SD, Bonifati C, Schena FP, Strippoli GF.
    J Nephrol; 2006 Nov 06; 19(5):640-7. PubMed ID: 17136694
    [Abstract] [Full Text] [Related]

  • 11. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM, White CM, Coleman CI.
    Clin Ther; 2008 Aug 06; 30(8):1416-25. PubMed ID: 18803985
    [Abstract] [Full Text] [Related]

  • 12. Update on erythropoietin treatment: should hemoglobin be normalized in patients with chronic kidney disease?
    Paoletti E, Cannella G.
    J Am Soc Nephrol; 2006 Apr 06; 17(4 Suppl 2):S74-7. PubMed ID: 16565252
    [Abstract] [Full Text] [Related]

  • 13. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
    Strippoli GF, Hodson EM, Jones C, Craig JC.
    Transplantation; 2006 Jan 27; 81(2):139-45. PubMed ID: 16436954
    [Abstract] [Full Text] [Related]

  • 14. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study.
    Go AS, Yang J, Ackerson LM, Lepper K, Robbins S, Massie BM, Shlipak MG.
    Circulation; 2006 Jun 13; 113(23):2713-23. PubMed ID: 16754803
    [Abstract] [Full Text] [Related]

  • 15. Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure.
    Parfrey PS.
    Curr Opin Nephrol Hypertens; 2011 Mar 13; 20(2):177-81. PubMed ID: 21157336
    [Abstract] [Full Text] [Related]

  • 16. From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy.
    Coyne DW.
    Semin Dial; 2008 Mar 13; 21(3):212-6. PubMed ID: 18363603
    [Abstract] [Full Text] [Related]

  • 17. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
    Provenzano R, Besarab A, Macdougall IC, Ellison DH, Maxwell AP, Sulowicz W, Klinger M, Rutkowski B, Correa-Rotter R, Dougherty FC, BA 16528 Study Investigators.
    Clin Nephrol; 2007 May 13; 67(5):306-17. PubMed ID: 17542340
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R, Epoetin Zeta Study Group.
    Curr Med Res Opin; 2008 Mar 13; 24(3):625-37. PubMed ID: 18208642
    [Abstract] [Full Text] [Related]

  • 19. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis.
    Amaral S, Hwang W, Fivush B, Neu A, Frankenfield D, Furth S.
    J Am Soc Nephrol; 2006 Oct 13; 17(10):2878-85. PubMed ID: 16943308
    [Abstract] [Full Text] [Related]

  • 20. [Anemia as a risk factor for CKD and CVD].
    Tsuruya K, Hirakata H.
    Nihon Rinsho; 2008 Sep 13; 66(9):1786-93. PubMed ID: 18788410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.